Virpax Pharmaceuticals Stock Fundamentals
| VRPX Stock | USD 0.46 0.02 4.17% |
Virpax Pharmaceuticals fundamentals help investors to digest information that contributes to Virpax Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Virpax Stock. The fundamental analysis module provides a way to measure Virpax Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Virpax Pharmaceuticals stock.
Net Interest Income is likely to rise to 987.74 in 2024, whereas Interest Expense is likely to drop slightly above 126.5 K in 2024. Virpax | Select Account or Indicator |
Virpax Pharmaceuticals Company Return On Equity Analysis
Virpax Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Virpax Pharmaceuticals Return On Equity | -3.62 |
Most of Virpax Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Virpax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Virpax Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Virpax Pharmaceuticals has a Return On Equity of -3.6229. This is 84.89% lower than that of the Biotechnology sector and 90.06% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Virpax Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Virpax Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Virpax Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Virpax Pharmaceuticals competition to find correlations between indicators driving Virpax Pharmaceuticals's intrinsic value. More Info.Virpax Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Virpax Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Virpax Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Virpax Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Virpax Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Virpax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Virpax Pharmaceuticals by comparing valuation metrics of similar companies.Virpax Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Virpax Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Virpax Pharmaceuticals from analyzing Virpax Pharmaceuticals' financial statements. These drivers represent accounts that assess Virpax Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Virpax Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 34.1M | 32.3M | 40.2M | 7.3M | 3.7M | 3.6M | |
| Enterprise Value | 35.3M | 33.8M | 3.3M | (11.7M) | (5.4M) | (5.1M) |
Virpax Fundamentals
| Return On Equity | -3.62 | ||||
| Return On Asset | -0.91 | ||||
| Current Valuation | 3.71 M | ||||
| Shares Outstanding | 4.89 M | ||||
| Shares Owned By Insiders | 2.57 % | ||||
| Shares Owned By Institutions | 0.03 % | ||||
| Number Of Shares Shorted | 315.03 K | ||||
| Price To Book | 0.48 X | ||||
| EBITDA | (2.25 M) | ||||
| Net Income | (15.19 M) | ||||
| Cash And Equivalents | 26.06 M | ||||
| Cash Per Share | 2.22 X | ||||
| Total Debt | 7.69 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 11.84 X | ||||
| Book Value Per Share | (0.98) X | ||||
| Cash Flow From Operations | (9.85 M) | ||||
| Short Ratio | 1.04 X | ||||
| Earnings Per Share | (13.25) X | ||||
| Target Price | 3.0 | ||||
| Beta | 1.1 | ||||
| Market Capitalization | 3.03 M | ||||
| Total Asset | 9.63 M | ||||
| Retained Earnings | (59.54 M) | ||||
| Working Capital | 1.93 M | ||||
| Net Asset | 9.63 M |
About Virpax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Virpax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virpax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virpax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -941 K | -893.9 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virpax Stock Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.